Background: Small cell lung carcinoma (SCLC) is characterized by -poor prognosis, -high predilection for -metastasis, -proliferation, and -absence of newer therapeutic options. Elucidation of newer pathways characterizing the disease may allow for development of targeted therapies and consequently favorable outcomes. Methods: The current study explored the combinatorial action of arsenic trioxide (ATO) and apatinib (APA) in vitro and in vivo. In vitro models were tested using -H446 and -H196 SCLC cell lines. The ability of drugs to reduce -metastasis, -cell proliferation, and -migration were assessed. Using bioinformatic analysis, differentially expressed genes were determined. Gene regulation was assessed using gene knock down models and confirmed using Western blots. The in vivo models were used to confirm the resolution of pathognomic features in the presence of the drugs. Growth factor receptor bound protein (GRB) 10 expression levels of human small cell lung cancer tissues and adjacent tissues were detected by IHC. Results: In combination, ATO and APA were found to significantly reduce -cell proliferation, -migration, and -metastasis in both the cell lines. Cell proliferation was found to be inhibited by activation of Caspase-3, -7 pathway. In the presence of drugs, it was found that expression of GRB10 was stabilized. The silencing of GRB10 was found to negatively regulate the VEGFR2/Akt/mTOR and Akt/GSK-3β/c-Myc signaling pathway. Concurrently, absence of metastasis and reduction of tumor volume were confirmed in vivo. The immunohistochemical results confirmed that the expression level of GRB10 in adjacent tissues was significantly higher than that in human small cell lung cancer tissues. Conclusions: Synergistically, ATO and APA have a more significant impact on inhibiting cell proliferation than each drug independently. ATO and APA may be mediating its action through the stabilization of GRB10 thus acting as a tumor suppressor. We thus, preliminarily report the impact of GRB10 stability as a target for SCLC treatment.
Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic and fatal interstitial lung disease. The etiology of IPF remains to be fully elucidated and its prognosis remains poor with a short survival period. Solute carrier family 7 member 5 (SLC7A5) is an amino acid transporter that is responsible for the transportation of large neutral amino acids. The expression of SLC7A5 was found to be significantly upregulated in patients with IPF, as well as in the lung tissues of mice with bleomycin (BLM)‑induced pulmonary fibrosis and in human lung fibroblasts induced by transforming growth factor‑β1 (TGF‑β1). Both SLC7A5 knockdown and the use of the selective SLC7A5 inhibitor JPH203 affected the function of TGF‑β1‑induced myofibroblasts by inhibiting the PI3K/AKT/mTOR pathway. In vivo, JPH203 improved BLM‑induced pulmonary fibrosis in mice by inhibiting the activation of the PI3K/AKT/mTOR signaling pathway. Therefore, SLC7A5 may represent a new therapeutic target for IPF. Future research should focus on therapeutic strategies regulating this target for translation into potential effective treatments for IPF in clinical practice.